生 命 科 学 研 究 圆园21 年
(上接第 556 页)
[15] 梁建萍. 植物学[M]. 北京: 中国农业出版社(LIANG Jian-ping.
Botany[M]. Beijing: China Agriculture Press), 2014: 246-304.
[16] 王文和, 关雪莲. 植物学[M]. 北京: 中国林业出版社(WANG
Wen-he, GUAN Xue-lian. Botany[M]. Beijing: China Forestry
Publishing House), 2015: 302-332.
[17] 马三梅, 王永飞. 植物生物学[M]. 北京: 科学出版社(MA Sanmei, WANG Yong-fei. Plant Biology[M]. Beijing: Science Press),
2017: 254-294.
[18] 杨世杰, 汪矛, 张志翔. 植物生物学[M]. 3 版. 北京: 高等教育出
版社(YANG Shi-jie, WANG Mao, ZHANG Zhi-xiang. Plant
Biology[M]. 3rd ed. Beijing: Higher Education Press), 2017:
280-329.
[19] 张宪省. 植物学[M]. 2 版. 北京: 中国农业出版社(ZHANG Xiansheng. Botany[M]. 2nd ed. Beijing: China Agriculture Press),
2014: 234-299.
[20] 胡宝忠, 张友民. 植物学[M]. 2 版. 北京: 中国农业出版社(HU
Bao-zhong, ZHANG You-min. Botany[M]. 2nd ed. Beijing: China Agriculture Press), 2011: 166.
[21] 陆时万, 徐祥生, 沈敏健. 植物学: 上册[M]. 2 版. 北京: 高等
教育出版社(LU Shi-wan, XU Xiang-sheng, SHEN Min-jian.
Botany (Vol. 1)[M]. 2nd ed. Beijing: Higher Education Press),
2011: 203-204.
[22] 叶创兴, 朱念德, 廖文波, 等. 植物学[M]. 2 版. 北京: 高等教
育出版社(YE Chuang-xing, ZHU Nian-de, LIAO Wen-bo, et al.
Botany[M]. 2nd ed. Beijing: Higher Education Press), 2014: 98-
374.
[23] 强胜. 植物学[M]. 2 版. 北京: 高等教育出版社(QIANG Sheng.
Botany[M]. 2nd ed. Beijing: Higher Education Press), 2017:
282-332.
[24] 金银根. 植物学[M]. 3 版. 北京: 科学出版社(JIN Yin-gen. Botany[M]. 3rd ed. Beijing: Science Press), 2018: 266-316.
[25] SINGH G. Plant Systematics: An Intergrated Approach[M]. 3rd
ed. Enfield: Science Publishers & Boca Raton: CRC Press, Taylor & Francis Group, 2010: 84, 503.
[26] 赵桂仿. 植物学[M]. 北京: 科学出版社(ZHAO Gui-fang. Botany[M]. Beijing: Science Press), 2009: 133-199.
[27] 周云龙, 刘全儒. 植物生物学[M]. 4 版. 北京: 高等教育出版
社(ZHOU Yun-long, LIU Quan-ru. Plant Biology[M]. 4th ed.
Beijing: Higher Education Press), 2016: 342-370.
[28] 吴万春. 植物学[M]. 2 版. 广州: 华南理工大学出版社(WU
Wan-chun. Botany[M]. 2nd ed. Guangzhou: South China University of Technology Press), 2004: 221-235.
[29] 吴国芳, 冯志坚, 马炜梁, 等. 植物学: 下册[M]. 2 版. 北京: 高
等教育出版社(WU Guo-fang, FENG Zhi-jian, MA Wei-liang,
et al. Botany (Vol. 2)[M]. 2nd ed. Beijing: Higher Education
Press), 1992: 214-353.
[30] 胡金良. 植物学[M]. 北京: 中国农业大学出版社(HU Jin-liang.
Botany[M]. Beijing: China Agriculture University Press), 2012:
221-234.
[31] RUDALL P J, STUPPY W, CUNNIFF J, et al. Evolution of reproductive structures in grasses (Poaceae) inferred by sistergroup comparison with their putative closest living relatives,
Ecdeiocoleaceae[J]. American Journal of Botany, 2005, 92(9):
1432-1443.
[32] CIAFFI M, PAOLACCI A R, TANZARELLA O A, et al. Molecular aspects of flower development in grasses[J]. Sexual Plant
Reproduction, 2011, 24(4): 247-282.
[33] ZHOU T Y, LU L L, YANG G, et al. Brassicaceae[M]//WU Z Y,
RAVEN P H, HONG D Y. Flora of China, Vol. 8. Beijing: Science Press & St. Louis: Missouri Botanical Garden Press, 2001:
1-193.
[34] LU L D, GU C Z, LI C L, et al. Rosaceae[M]//WU Z Y, RAVEN P
H, HONG D Y. Flora of China, Vol. 9. Beijing: Science Press
& St. Louis: Missouri Botanical Garden Press, 2003: 1-430.
[40] LONGO V, BRUNETTI O, AZZARITI A, et al. Strategies to
improve cancer immune checkpoint inhibitors efficacy, other
than abscopal effect: a systematic review[J]. Cancers, 2019, 11
(4): 539.
[41] FORCE J, LEAL J H S, MCARTHUR H L. Checkpoint blockade
strategies in the treatment of breast cancer: where we are and
where we are heading[J]. Current Treatment Options in Oncol原
ogy, 2019, 20(4): 35.
[42] O忆DONNELL J S, LONG G V, SCOLYER R A, et al. Resis原
tance to PD1/PDL1 checkpoint inhibition[J]. Cancer Treatment
Reviews, 2017, 52: 71-81.
[43] CONSTANTINIDOU A, ALIFIERIS C, TRAFALIS D T. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a
new era in cancer active immunotherapy[J]. Pharmacology &
Therapeutics, 2019, 194: 84-106.
[44] GE H, YAN Y, TIAN F, et al. Prognostic value of estrogen receptor 琢 and estrogen receptor 茁 in gastric cancer based on a
meta-analysis and The Cancer Genome Atlas (TCGA) datasets[J].
International Journal of Surgery, 2018, 53: 24-31.
[45] QIN T, LI B, FENG X, et al. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity[J]. Journal
of Experimental & Clinical Cancer Research, 2018, 37(1): 287-
293.
[46] PATEL S P, KURZROCK R. PD-L1 expression as a predictive
biomarker in cancer immunotherapy[J]. Molecular Cancer Therapeutics, 2015, 14(4): 847-856.
[47] CHOUEIRI T K, FAY A P, GRAY K P, et al. PD-L1 expres原
sion in nonclear-cell renal cell carcinoma[J]. Annals of Oncology, 2014, 25(11): 2178-2184.
[48] SCHALPER K A, VELCHETI V, CARVAJAL D, et al. In situ
tumor PD-L1 mRNA expression is associated with increased
TILs and better outcome in breast carcinomas[J]. Clinical Cancer Research, 2014, 20(10): 2773-2782.
[49] YANG C Y, LIN M W, CHANG Y L, et al. Programmed cell
death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage玉
pulmonary squamous cell carcinoma[J]. European Journal of
Cancer, 2016, 57: 91-103.
[50] ZHANG Y, KANG S, SHEN J, et al. Prognostic significance of
programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1)
expression in epithelial-originated cancer: a meta-analysis[J].
Medicine, 2015, 94(6): e515.
[51] KIM S, NAM S J, PARK C, et al. High tumoral PD-L1 expression and low PD-1 +
or CD8 +
tumor -infiltrating lymphocytes
are predictive of a poor prognosis in primary diffuse large B-cell
lymphoma of the central nervous system[J]. Oncoimmunology,
2019, 8(9): e1626653.
[52] LU J C, ZENG H Y, SUN Q M, et al. Distinct PD-L1/PD1
profiles and clinical implications in intrahepatic cholangiocar原
cinoma patients with different risk factors[J]. Theranostics, 2019,
9(16): 4678-4686.
[53] UHERCIK M, SANDERS A J, OWEN S, et al. Clinical signifi原
cance of PD1 and PDL1 in human breast cancer[J]. Anticancer
Research, 2017, 37(8): 4249-4254.
[54] HOU Y, NITTA H, WEI L, et al. PD-L1 expression and CD8-
positive T cells are associated with favorable survival in HER2-
positive invasive breast cancer[J]. The Breast Journal, 2018, 24
(6): 911-919.
[55] ZHU X, ZHANG Q, WANG D, et al. Expression of PD-L1 attenuates the positive impacts of high-level tumor-infiltrating
lymphocytes on prognosis of triple-negative breast cancer[J].
Cancer Biology & Therapy, 2019, 20(8): 1105-1112.
564